nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft modelData support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES, May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-385 ...

Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Dave Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Tara Bancroft - TD Cowen Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscien ...

PRESS RELEASE Exhibit 99.1 Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES, CA, May 8, 2024 – Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-sta ...

Company to Host Conference Call and Webcast on May 8, 2024LOS ANGELES, May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates.Conference Call Inf ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aadi Bioscience, Inc. (AADI) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aadi Bioscience, Inc. is one of 1054 individual stocks in the Medical sector. Collectively, the ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aadi Bioscience, Inc. (AADI) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aadi Bioscience, Inc. is one of 1064 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 differen ...

Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers LOS ANGELES, March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers w ...

Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Conference Call March 13, 2024 8:30 AM ET Company Participants Dave Lennon - President and CEO Scott Giacobello - CFO Loretta Itri - Chief Medical Officer Conference Call Participants Joe Catanzaro - Piper Sandler Liang Cheng - Jefferies Ahu Demir - Ladenburg Operator Good day, and thank you for standing by. Welcome to Aadi Bioscience Fourth Quarter 2023 Earnings Conference Call. At this time, more participants are in a listen-only-mode. After the speaker ...

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.45%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.60, delivering a surprise of 17.81%.Over the last four quarters, the company has su ...